PL1990410T3 - Immunoterapia komórkami zdolnymi do ekspresji antygenu docelowego i CD1D oraz pulsowanymi ligandem CD1D - Google Patents

Immunoterapia komórkami zdolnymi do ekspresji antygenu docelowego i CD1D oraz pulsowanymi ligandem CD1D

Info

Publication number
PL1990410T3
PL1990410T3 PL07714709T PL07714709T PL1990410T3 PL 1990410 T3 PL1990410 T3 PL 1990410T3 PL 07714709 T PL07714709 T PL 07714709T PL 07714709 T PL07714709 T PL 07714709T PL 1990410 T3 PL1990410 T3 PL 1990410T3
Authority
PL
Poland
Prior art keywords
cd1d
immunotherapy
pulsed
expressing
target antigen
Prior art date
Application number
PL07714709T
Other languages
English (en)
Inventor
Shin-Ichiro Fujii
Kanako Shimizu
Original Assignee
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken filed Critical Riken
Publication of PL1990410T3 publication Critical patent/PL1990410T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07714709T 2006-02-22 2007-02-21 Immunoterapia komórkami zdolnymi do ekspresji antygenu docelowego i CD1D oraz pulsowanymi ligandem CD1D PL1990410T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006045193 2006-02-22
EP07714709.8A EP1990410B1 (en) 2006-02-22 2007-02-21 IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND
PCT/JP2007/053209 WO2007097370A1 (ja) 2006-02-22 2007-02-21 ＣＤ１ｄリガンドをパルスした、標的抗原及びＣＤ１ｄの共発現細胞による免疫療法

Publications (1)

Publication Number Publication Date
PL1990410T3 true PL1990410T3 (pl) 2020-07-13

Family

ID=38437409

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07714709T PL1990410T3 (pl) 2006-02-22 2007-02-21 Immunoterapia komórkami zdolnymi do ekspresji antygenu docelowego i CD1D oraz pulsowanymi ligandem CD1D

Country Status (12)

Country Link
US (1) US20100233215A1 (pl)
EP (2) EP2441468B1 (pl)
JP (2) JP5672647B2 (pl)
CY (1) CY1122911T1 (pl)
DK (1) DK1990410T3 (pl)
ES (2) ES2774707T3 (pl)
HU (1) HUE049283T2 (pl)
LT (1) LT1990410T (pl)
PL (1) PL1990410T3 (pl)
PT (1) PT1990410T (pl)
SI (1) SI1990410T1 (pl)
WO (1) WO2007097370A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1916310B1 (en) * 2005-06-17 2018-09-26 Riken Method for analysis of nkt cell function
ES2774707T3 (es) * 2006-02-22 2020-07-22 Riken Inmunoterapia mediante la utilización de células capaces de co-expresar un antígeno diana y CD1d y pulsadas con un ligando de CD1d
US20100330057A1 (en) * 2007-09-10 2010-12-30 Riken Method of evaluating human dentritic cells and human cell immunotherapeutic agent
KR100995340B1 (ko) * 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신
JPWO2010061930A1 (ja) 2008-11-28 2012-04-26 独立行政法人理化学研究所 ＣＤ１ｄ及び標的抗原の共発現アロ細胞を用いた免疫療法
US9783821B2 (en) 2011-07-29 2017-10-10 Riken Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
US10316332B2 (en) 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
JP6687246B2 (ja) * 2014-12-11 2020-04-22 国立研究開発法人理化学研究所 改変型免疫細胞、改変型免疫細胞の製造方法、およびこれらの利用
AU2016212777B2 (en) * 2015-01-27 2021-11-18 LAVA Therapeutics N.V. Single domain antibodies targeting CD1d
JP7125760B2 (ja) * 2019-06-14 2022-08-25 国立研究開発法人理化学研究所 免疫系を賦活化する細胞および当該細胞を含む医薬組成物
EP4011389A4 (en) * 2019-08-09 2024-09-04 Riken COMBINED USE OF ARTIFICIAL AUXILIARY VECTOR CELLS AND IMMUNE STIMULANT
CR20220319A (es) * 2019-12-02 2022-11-03 Riken MÉTODO PARA EL TRATAMIENTO DE CÁNCER UTILIZANDO CÉLULA ADYUVANTE ARTIFICIAL (aAVC)
JP7646213B2 (ja) * 2019-12-02 2025-03-17 国立研究開発法人理化学研究所 がんの処置に用いるｎｙ－ｅｓｏ－１含有人工アジュバントベクター細胞
JP2023078487A (ja) * 2020-04-08 2023-06-07 アステラス製薬株式会社 がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞
WO2022230971A1 (ja) 2021-04-30 2022-11-03 国立研究開発法人理化学研究所 コロナウイルスに対する免疫応答を誘発する人工アジュバントベクター細胞、および当該細胞を含む医薬組成物、並びにそれらの使用
WO2024147357A1 (ja) * 2023-01-06 2024-07-11 株式会社アクセルベックス 癌免疫療法に使用するための癌細胞の調製方法、及び該癌細胞による癌の治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010419A2 (en) 1994-10-03 1996-04-11 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
JP2002112780A (ja) 2000-10-03 2002-04-16 Keio Gijuku ヒト膀胱癌抗原
JP2004147649A (ja) 2002-10-11 2004-05-27 Kumamoto Technology & Industry Foundation 頭頚部癌の抗原
HU0301358D0 (en) * 2003-05-14 2003-07-28 Debreceni Egyetem Novel use of ppargamma agonists
JP2005139118A (ja) 2003-11-07 2005-06-02 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
JP5002915B2 (ja) 2004-07-01 2012-08-15 住友化学株式会社 光学活性なシクロプロパンカルボン酸エステル化合物の製造方法およびそれに用いる不斉銅錯体
WO2007043630A1 (ja) * 2005-10-06 2007-04-19 Riken 上気道粘膜下に投与されるｎｋｔ細胞刺激剤
ES2774707T3 (es) * 2006-02-22 2020-07-22 Riken Inmunoterapia mediante la utilización de células capaces de co-expresar un antígeno diana y CD1d y pulsadas con un ligando de CD1d
US10316332B2 (en) * 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
CR20220319A (es) * 2019-12-02 2022-11-03 Riken MÉTODO PARA EL TRATAMIENTO DE CÁNCER UTILIZANDO CÉLULA ADYUVANTE ARTIFICIAL (aAVC)

Also Published As

Publication number Publication date
WO2007097370A1 (ja) 2007-08-30
CY1122911T1 (el) 2021-10-29
LT1990410T (lt) 2020-03-10
JPWO2007097370A1 (ja) 2009-07-16
EP2441468A2 (en) 2012-04-18
ES2774707T3 (es) 2020-07-22
EP2441468B1 (en) 2020-01-08
PT1990410T (pt) 2020-03-03
DK1990410T3 (da) 2020-04-06
SI1990410T1 (sl) 2020-07-31
ES2780176T3 (es) 2020-08-24
HUE049283T2 (hu) 2020-09-28
EP1990410A4 (en) 2009-08-26
US20100233215A1 (en) 2010-09-16
EP2441468A3 (en) 2012-10-17
JP5672647B2 (ja) 2015-02-18
EP1990410A1 (en) 2008-11-12
JP5673723B2 (ja) 2015-02-18
JP2013212107A (ja) 2013-10-17
EP1990410B1 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
SI1990410T1 (sl) Imunoterapija z uporabo celice, sposobne soizražanja ciljnega antigena in CD1d ter pulzirane z ligandom CD1d
CY2020021I1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
CY2021009I2 (el) Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι χρησης αυτων στην αντιμετωπιση φλεγμονωδων νοσων
IL210768B (en) Antibodies targeting complement protein c5 and compositions comprising them
EP2371333A4 (en) THIN CLEANER ARTICLE
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
IL213116B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
PL2358756T5 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI0914319A2 (pt) anticorpos estáveis e solúveis que inibem tnfalfa
BRPI0821110A2 (pt) Anticorpo anti nr-10 e uso do mesmo
PL3042917T3 (pl) Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
PL2942355T3 (pl) Nie-hemolityczne białka fuzyjne llo i ich zastosowanie
BRPI0716300A2 (pt) Artigo e mistura
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
PL1824887T3 (pl) Przeciwciało cytotoksyczne skierowane przeciwko proliferacjom krwiotwórczych komórek limfatycznych typu B
DK4209510T3 (da) Anti-pd-l1-antistoffer og deres anvendelse til at fremme t-cellefunktion
EP2352816A4 (en) HUMAN TEMPORARY CELLS
PL2437051T3 (pl) System pseudo dwuenergetyczny i metoda identyfikacji materiałów z wykorzystaniem podpróbkowania
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
SE0802254L (sv) Stoppsystem och stoppmetoder
EP2209114A4 (en) ENCODER AND DECODER
IL236516B (en) Antibodies and compositions comprising them for treatment of cancer
EP3505536C0 (de) Antikörper gegen das prostata-spezifische stammzellantigen und dessen verwendung
IT1394876B1 (it) "mezzi per la duplicazione di una chiave codificata elettronicamente e relativo procedimento di duplicazione"